S-1: SS Innovations International Files for IPO to Fuel Surgical Robotics Expansion

SS Innovations International, a surgical robotics company, is seeking to raise capital through an IPO to expand its manufacturing capacity, conduct clinical trials, and establish marketing offices.

Summary

• SS Innovations International, Inc., a Florida corporation, has filed a Form S-1 registration statement with the SEC for an underwritten public offering of its common stock.
• The company aims to list its common stock on the Nasdaq Capital Market under the symbol SSII, although there is no guarantee of successful listing.
• The preliminary prospectus indicates an offering price of $ per share, with the company seeking to raise approximately $ million before expenses.
• SS Innovations intends to use the net proceeds for working capital and general corporate purposes, including expanding manufacturing capacity, ordering components, conducting clinical trials, and establishing regional marketing offices.
• The company's core product is the SSi Mantra Surgical Robotic System, designed to provide an advanced and affordable alternative to existing robotic surgery systems.
• As of the date of the prospectus, the company has installed 23 systems, with 21 in India, one in Dubai, and one at Johns Hopkins Hospital for training and research.
• The company generates revenue from the sale of the SSi Mantra system through outright purchase, deferred payment plans, and pay-per-procedure models, as well as recurring revenue from instruments, accessories, and services.
• The company faces significant risks, including a limited operating history, potential for continued losses, the need for additional financing, and the challenge of achieving market acceptance for its products.
• The company is an emerging growth company and has elected to comply with certain reduced public company reporting requirements.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company highlights the potential of its technology and the growth of the surgical robotics market, it also acknowledges significant risks and challenges, including a limited operating history, potential for continued losses, and the need for additional financing. The sentiment is cautiously optimistic.

Positives

• The SSi Mantra Surgical Robotic System offers an advanced technology at a significantly lower cost than existing systems.
• The company has already obtained regulatory approval in India, the United Arab Emirates and Guatemala, allowing it to market its products in several countries.
• The company has a built-in live streaming platform, which provides for remote proctoring, thereby resulting in efficient and cost-effective teaching and training capabilities.
• The company has a comprehensive suite of stapling, energy and core instrumentation for our surgical systems, under the brand name of SSi Mudra.

Negatives

• The company has a limited operating history and has incurred losses since its inception.
• The company may require significant additional financing to expand marketing of its SSi Mantra system, obtain regulatory approvals in the United States, the EU and other countries where it wishes to market its products, and develop and commercialize enhancements to its surgical robotic system, as well as other related products.
• The SSi Mantra and our other products and operations have not been approved for marketing in the United States or the EU, and are and will be subject to extensive and rigorous government regulation in India by CDSCO, by the FDA in the United States, and by similar agencies in the EU and many other countries where we plan to market our products.

Risks

• The company may not be able to generate revenue on a consistent basis or operate on a profitable basis.
• The company may not be able to obtain additional financing when needed or on acceptable terms.
• The SSi Mantra Surgical Robotic System may not achieve market acceptance.
• The company may encounter resistance from customers to the effort required to be trained to use the SSi Mantra and other problems or delays with respect to training that could result in lost revenue.
• The company may encounter manufacturing problems or delays that could result in lost revenue.
• The company may be subject to claims by third parties claiming ownership of what we regard as our own intellectual property.

Future Outlook

The company believes that the net proceeds from this offering, together with its existing cash and cash equivalents and revenues that it anticipates generating from sales of its robotic surgery systems, will be sufficient to fund its operations through 2027.

Industry Context

The global surgical robotics market is projected to reach $37.5 billion by 2032, growing at a CAGR of 19.9% from 2023 to 2032, indicating a significant growth opportunity for companies in this sector.

Comparison to Industry Standards

• The company competes with established players like Intuitive Surgical, Asensus Surgical, Johnson & Johnson, and Medtronic, many of which have greater experience and financial resources.
• The company believes that the primary competitive factors in the market it addresses will be procedural capability, cost of operations, efficacy, ease of use, quality, reliability, and effective sales support, training and service.

Management Changes

Legal Proceedings

• Currently there are no legal proceedings pending or threatened against us.

Related Party Transactions

• On April 15, 2023, the Company executed a Convertible Promissory Note (the Line of Credit Note) with Sushruta
• The Company has sold two surgical robotic systems to Aster Hospitals group
• Dr Sudhir Kumar Rawal, a director on the board of SSI India, a subsidiary of the Company, beneficially owns 477,084 restricted shares of our common stock awarded to him under the Incentive Plan towards his medical advisory and proctorship services for a period of five years.

Stakeholder Impact

• The company's success depends on continued clinical and technical innovation, quality and reliability, as well as educating hospitals, surgeons and patients on the demonstrated results associated with robotic-assisted medical procedures using our SSi Mantra Surgical Robotic System and its efficacy and cost-effectiveness relative to other techniques.

Next Steps

• The company intends to expand its manufacturing capacity through the installation of additional machinery and equipment.
• The company intends to bulk order components for use in manufacturing of our final products.
• The company intends to conduct global clinical trials to meet various regulatory requirements.
• The company intends to establish regional marketing offices.

Key Dates

Keywords

surgical robotics, SSi Mantra, IPO, medical devices, robotic surgery, healthcare, FDA, regulatory approval, India, surgical systems